低危甲状腺癌患者接受与未接受放射性碘治疗的长期相对生存:基于SEER数据库的组织学亚型与危险因素分析
该研究基于SEER数据库纳入18,645例符合ESTIMABL2标准的低危分化型甲状腺癌患者,回顾性分析长期相对生存。结果显示,滤泡状甲状腺癌患者接受放射性碘治疗后5年和10年相对生存分别提高0.3%(p=0.029)和2.3%(p=0.055);无淋巴结转移的乳头状甲状腺癌患者未见生存差异;伴淋巴结转移的pT1b组患者10年相对生存提高2.6%(p=0.023)。
要点
- 滤泡状甲状腺癌患者接受放射性碘治疗5年相对生存提高0.3%(p=0.029)。
- 伴淋巴结转移的pT1b乳头状甲状腺癌患者10年相对生存提高2.6%(p=0.023)。
- 无淋巴结转移的乳头状甲状腺癌患者接受放射性碘治疗未见生存差异。
核心结论
- 按ESTIMABL2标准筛选的低危分化型甲状腺癌中,特定亚组接受放射性碘治疗与更高的长期相对生存相关。
- 滤泡状甲状腺癌患者放射性碘治疗5年后相对生存更高,10年差异为2.3%(p=0.055)。
- 伴淋巴结转移的乳头状甲状腺癌患者放射性碘治疗后10年相对生存更高。
研究设计与样本
- 基于SEER数据库的回顾性分析,纳入18,645例符合ESTIMABL2试验标准的低危分化型甲状腺癌患者。
- 另在5,171例伴淋巴结受累(N1)患者中分析。
- 按组织学(乳头状与滤泡状)及TNM状态分层,比较3年、5年和10年相对生存。
主要发现
- 滤泡状甲状腺癌患者接受放射性碘治疗后5年相对生存提高0.3%(p=0.029),10年提高2.3%(p=0.055),3年差异0.2%(p=0.150)。
- 无淋巴结转移的乳头状甲状腺癌患者接受与未接受放射性碘治疗之间未检测到生存差异。
- 伴淋巴结转移的pT1b组患者接受放射性碘治疗后10年相对生存提高2.6%(p=0.023)。
关键数值与推荐
- 低危分化型甲状腺癌定义采用ESTIMABL2试验标准:pT1am-pT1b、N0-NX的乳头状和滤泡状甲状腺癌。
临床怎么用
- 对低危分化型甲状腺癌,可依据组织学亚型和淋巴结状态个体化评估放射性碘治疗获益。
- 滤泡状甲状腺癌和伴淋巴结转移的乳头状甲状腺癌患者可能从放射性碘治疗中获得长期生存获益。
- 无淋巴结转移的乳头状甲状腺癌患者接受放射性碘治疗未见长期生存获益。
局限性
- 为回顾性SEER数据库分析,非随机对照设计。
- 随访时间超过10年,但部分亚组事件数可能有限。
- 滤泡状甲状腺癌10年差异p=0.055,未达传统统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The ESTIMABL2-trial demonstrated non-inferiority of avoiding radioiodine therapy in low-risk differentiated thyroid cancer (DTC, i.e. papillary- and follicular thyroid cancer (PTC, FTC)). Yet, follow-up duration was limited and FTC were underrepresented. We therefore assessed long-term relative survival by comparing observed and expected cancer-free survival. This robust measure of net survival was used to evaluate the long-term effects of radioiodine therapy, including in previously underrepresented histological subgroups. METHODS: Using the SEER-database, we identified 18,645 patients with DTC according to the criteria in the ESTIMABL2-trial (low risk PTC and FTC with pT1am-pT1b, N0-NX). Long-term relative survival (> 10 years) was analysed retrospectively, subdivided based on histology (PTC and FTC) and TNM-status, and additionally in 5,171 patients with lymph node involvement (N1). Relative survival was compared at 3 -, 5 -, and 10-years follow-up with and without radioiodine. RESULTS: Radioiodine therapy was associated with higher long-term relative survival in specific subgroups: Among FTC patients, relative survival was higher with radioiodine after 5- and, 10-years by 0.3% (p = 0.029), and 2.3% (p = 0.055), not after three years (0.2%, p = 0.150). For PTC without lymph node involvement, no survival difference was detected. With lymph node involvement, relative survival was higher in the radioiodine-group after 10 years (pT1b group with 2.6% difference, p = 0.023). CONCLUSION: Depending on histology, subgroups of patients with low-risk DTC selected from the SEER-database according to ESTIMABL2-criteria, have a higher survival after radioiodine therapy, notably in FTC patients after more than 5 years. Furthermore, PTC patients with lymph node involvement revealed higher relative survival after 10 years. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-026-07888-1.
引用
- Weis H, Schmidt K, Heilinger J, et al. Long-term relative survival with and without radioiodine in patients with low-risk thyroid cancer: a SEER based analysis of histologic subtypes and risk factors. Eur J Nucl Med Mol Imaging. 2026. PMID: 42071107. doi:10.1007/s00259-026-07888-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。